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Conclusions: Essentially, we found it possible to use Archetypes 
and Templates to integrate a test set of intensive care data from 2 
systems. By applying the openEHR approach for data modeling and 
integration, detailed clinical models can be used for tasks such as 
automated constraint checking, error reporting, data persistence, and 
querying. Although medical scores such as the Glasgow Coma Scale 
were a good fit for openEHR, voluminous data such as vital signs 
and ventilation data needed some workarounds to work properly. 
Especially, the demand of archetypes to be explicit about the meaning 
of each data element might be problematic in some data integration 
scenarios. On the one hand, this might be considered an advantage, 
as it forces EDW developers and system analysts to work thoroughly. 
On the other hand, this constraint might prevent pragmatic solutions 
when a fast integration cannot be achieved or interpretation of data 
can be conducted by the end-users. Although this work illustrates 
some of the strengths and restrictions of the openEHR approach for 
data integration tasks, our methodology is limited by the number 
of used clinical concepts. A possible next step is the investigation of 
the implications of openEHR-based information retrieval and the 
semantic interpretation of data.
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Background: The medical devices sector helps save lives by provid-
ing innovative health care solutions regarding diagnosis, prevention, 
monitoring, treatment, and alleviation. Medical devices are classified 
into 1 of 3 categories in the order of increasing risk: Class I, Class II, 
and Class III.1 Medical devices are distinguished from drugs for 
regulatory purposes based on mechanism of action. Unlike drugs, 
medical devices operate via physical or mechanical means and are 
not dependent on metabolism to accomplish their primary intended 
effect.2,3
Objectives: This study focused on regulations and differences in med-
ical device and pharmaceutical drug development. It also highlighted 
the unique challenges faced while doing medical device development.
Methods: A US Food and Drug Administration and European 
Medicines Agency website search was conducted to determine cur-
rent medical device regulations. A comprehensive literature search 
was done from Google Scholar to determine the differences in drug 
and medical device development.
Results: Designing well-controlled prospective clinical trials of 
medical devices presents unique challenges that differ from those 
faced in studies of pharmaceuticals. Clinical outcomes observed in 
medical device studies, unlike drug trials, are influenced not only by 
the product under evaluation and the patient but also by the skill 
and discretion of the health care professional. Medically appropri-
ate alternative treatment regimens may not be available to provide 
randomized, concurrent controls in device trials. Because devices are 
often developed by small companies, financial constraints often limit 
the new product development and testing.
Conclusions: Medical device development is faced with unique chal-
lenges. Managing the design issues in clinical trials and complying 
with increasingly stringent regulatory guidelines is necessary to bring 
new devices faster to market with reduced cost.
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Increasingly, hospitals and other players in the health care sector will 
inevitably compete in terms of quality. Interinstitutional and cross-
sectoral quality assurance has been pushed forward during recent 
years. Institution-related outcomes are published and accessible to 
the public. Due to new health laws, in the near future, quality results 
of hospitals will not only be decisive for reimbursement increases or 
price reductions of the remuneration but will also be a crucial factor 
for a hospital’s survival. Hospitals that are not able to get quality 
deficiencies under control may lose their public supply mandate. 
Thus, the outcome of hospitals should be measured on the basis 
of predefined quality indicators to reach the objectives described 
earlier. Key indicators are, on the one hand, measures of medical 
performance. In particular, these include, for example, the type and 
numbers of surgical procedures as well as surgical complications in 
a certain time period. Also included are structural statistics about 
continuous medical education such as number of passed training 
courses for medical doctors and nurses. Moreover, information about 
patient safety are key indicators for quality assurance. Patient safety 
indicators, for example, are the number of patient falls and side 
effects of medication. These parameters have to be registered in a 
structured form and in a fixed frequency. The method to provide 
these indicators is a continuous comprehensive quality management, 
including capturing and monitoring of all relevant data. This requires 
the establishment of a professional operating system gaining all neces-
sary figures in daily clinical routine. Health information management 
